Insider Selling: TG Therapeutics, Inc. (NASDAQ:TGTX) Director Sells 5,000 Shares of Stock

TG Therapeutics, Inc. (NASDAQ:TGTX) Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the sale, the director now owns 100,195 shares in the company, valued at approximately $3,049,935.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX opened at $34.90 on Thursday. TG Therapeutics, Inc. has a 1 year low of $10.42 and a 1 year high of $36.24. The firm has a market cap of $5.43 billion, a P/E ratio of -349.00 and a beta of 2.19. The stock has a fifty day moving average price of $24.41 and a two-hundred day moving average price of $20.89. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company’s quarterly revenue was down 49.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.73 EPS. Research analysts forecast that TG Therapeutics, Inc. will post 0.17 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TGTX has been the topic of several analyst reports. TD Cowen assumed coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price target on the stock. The Goldman Sachs Group raised their target price on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. B. Riley boosted their price target on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, HC Wainwright lifted their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, TG Therapeutics has an average rating of “Moderate Buy” and an average target price of $37.67.

Hedge Funds Weigh In On TG Therapeutics

Several large investors have recently made changes to their positions in the business. Opaleye Management Inc. raised its holdings in shares of TG Therapeutics by 2.9% in the 1st quarter. Opaleye Management Inc. now owns 2,280,000 shares of the biopharmaceutical company’s stock worth $34,679,000 after purchasing an additional 65,000 shares in the last quarter. Marshall Wace LLP acquired a new position in TG Therapeutics in the second quarter worth approximately $36,501,000. Hood River Capital Management LLC increased its holdings in shares of TG Therapeutics by 6.7% in the second quarter. Hood River Capital Management LLC now owns 1,572,929 shares of the biopharmaceutical company’s stock valued at $27,982,000 after buying an additional 98,892 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of TG Therapeutics by 0.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,184,609 shares of the biopharmaceutical company’s stock valued at $27,708,000 after acquiring an additional 7,939 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of TG Therapeutics by 1,549.4% during the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after acquiring an additional 725,371 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.